Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety and Immunogenicity Study of DNK-651 in Healthy Japanese Adults
jRCT2080223171Phase 1
- Sponsor
- Denka
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of DNK-651 in Infection prevention (IPC) (2 arms), sponsored by Denka. Primary endpoints: Safety of DNK-651 and Immunogenicity of DNK-651.
02
Drugs
DNK-651
03
Conditions
Infection prevention (IPC)
Beyond the preview
Go deeper on jRCT2080223171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223171.